RYTM — Rhythm Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $3.02bn
- $2.93bn
- $77.43m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 292 | 173 | 295 | 333 | 276 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | 1.02 | 6.22 | 14.9 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 302 | 182 | 308 | 354 | 308 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5.72 | 5 | 4.33 | 3.38 | 2.12 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 309 | 187 | 330 | 382 | 333 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 24.4 | 18 | 43.4 | 39.8 | 55.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 27.5 | 20.5 | 45.4 | 118 | 163 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 281 | 167 | 284 | 264 | 170 |
Total Liabilities & Shareholders' Equity | 309 | 187 | 330 | 382 | 333 |
Total Common Shares Outstanding |